Calendario›DMAC›DM199
DM199
A Study to Evaluate the Safety and Effectiveness of DM199 in Healthy Subjects and Type 2 Diabetes Patients
Ensayo de DiaMedica Therapeutics Inc. en Diabetes Type 2 (del registro, en inglés).
- Fase
- Fase 1/2
- Estado
- Completado
- Participantes
- 98
- Centros
- 1
- Fin del objetivo primario
- sep 2014
previstos
fecha real
Qué significa cada fase y cada estado.
Estudio de intervención, aleatorizado, cuádruple ciego. Comenzó en abr 2013.
Qué mide
Safety and tolerability of single and multiple subcutaneous doses of DM199 (Up to 13 days after final dose) (del registro, en inglés)
Cómo lo describe el promotor
En el documentoEn inglés, del registroDM199 (recombinant human tissue kallikrein-1) is a new investigational compound that may eventually be used for the treatment of Diabetes Mellitus Type 2. This is the first time that this compound is being given to humans. The purpose of the study is to investigate to what extent DM199 is safe and tolerated. Further, it will be investigated how quickly and to what extent DM99 is absorbed and eliminated from the body (this is called pharmacokinetics). In addition, the effect of the compound on the body will be investigated (this is called pharmacodynamics). This study is not intended to improve anyone's health, but is necessary for the further development of DM199. The study consists of 4 parts. Each part (A, B, C and D) will consist of one or several periods. The research will be conducted in healthy male and female volunteers (Part A and C) and in male and female type 2 diabetes mellitus patients (Part B and D).
Más ensayos de DMAC
| Ensayo | Fase | Estado | Lectura de resultados |
|---|---|---|---|
| ReMEDy2 | Fase 2/3 | Reclutando pacientes | dic 2026 (prevista) |
| DM199 | Sin fase asignada | Retirado antes de empezar | may 2025 (prevista, ya pasada: sin actualizar en el registro) |
| DM199 | Fase 2 | Completado | mar 2022 (real) |
| ReMEDy1 | Fase 2 | Completado | ene 2020 (real) |
| DM199 | Fase 1 | Completado | jul 2019 (real) |
| Recombinant human tissue… | Fase 1 | Completado | mar 2017 (real) |
Todos los de DMAC, en su ficha.
Ficha completa en ClinicalTrials.gov (NCT01845064), actualizada en dic 2014.